



October 7, 2019

Gene Techno Science Co., Ltd.

Summit Pharmaceuticals International Corporation

**Signed a Contract for Sale of
Stem Cells from Human Exfoliated Deciduous Teeth
between Gene Techno Science Co., Ltd.
and Summit Pharmaceuticals International Corporation.**

Tokyo, October 7, 2019 – Gene Techno Science Co., Ltd. (“GTS”) and Summit Pharmaceuticals International Corporation (“SPI”) announced that Advanced Cell Technology and Engineering Ltd. (“ACTE”), a subsidiary of GTS, and SPI have signed a contract regarding the sale of stem cells from human exfoliated deciduous teeth (“SHEDs”) manufactured by ACTE. We are currently preparing for the product launch and are expected to start supplying SHEDs soon.

Mesenchymal stem cells (“MSCs”) from bone marrow, umbilical cord, and adipose tissue have been supplied and utilized in many years; however, researchers in recent years found MSCs inside a teeth, from a tissue called dental pulp (SHEDs). SHEDs have advantages such as easiness to collect due to less burden and risk to donors and high proliferation capability, which results in shorter cell culture time to obtain high-quality stem cells. Moreover, SHEDs have characteristics as high differentiation potency and relatively low immunogenicity like other MSCs. From these characteristics, SHEDs are expected to be utilized in variety of research projects including application to cell therapy and regenerative medicine.

Through the collaboration between ACTE and SPI, we would like to rapidly and stably supply SHEDs to researchers in Japan and overseas, which are collected, processed and

stored through the ACTE's platform by using cold chain logistics and sales channels that SPI has accumulated over the years in the sale of biological resources, and then accelerate research and development of new therapeutic treatment.

About Gene Techno Science Co., Ltd.

GTS announced GTS 3.0 “Biotech Engineering Company, striving for value creation” a new business stage starting from this fiscal year, which targeted the pediatric disease in addition to the areas GTS has been engaged in such as the orphan disease and intractable disease. By leveraging the knowhow and expertise about biotechnology acquired in the past business activities, GTS is working on the development and provision of new medicines and therapeutic treatment for the purpose of achieving comprehensive healthcare solutions for the patients suffering from these diseases as well as families and caregivers. This contract aims to accelerate the realization of new therapeutic treatments by using SHEDs, which is the cornerstone of GTS business in cell therapy field.

About Summit Pharmaceuticals International Corporation

SPI is a provider of high-quality integrated products and services to pharmaceutical industry, from research equipment and bioresources for drug discovery, pharmaceutical licensing and research alliance support, to manufacturing of APIs, intermediates for pharmaceuticals, generic drugs and biologics. SPI is the provider of biological materials of ATCC, the world biggest company of gene/cell bank for researches based in the U.S. SPI is 100% owned subsidiary company of Sumitomo Corporation which is one of the leading global trading company with 111 locations in 66 countries and 22 locations in Japan (as of April 1, 2019) with diverse range of products and services and plays a central role in the medical science business line as a group company of Sumitomo Corporation.

Inquiries:

Gene Techno Science Co., Ltd.

Tel: +81-3-6222-9547 Mail: info@g-gts.com

Summit Pharmaceuticals International Corporation

Tel: +81-3-5220-1560 Mail: alliance@summitpharma.co.jp